Avid Bioservices Inc 's ROA from the second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Avid Bioservices Inc 's ROA in the second quarter of 2025?
Avid Bioservices Inc recorded a cumulative net loss of $-152 million during 12 months ending in the second quarter of 2025, resulting in a negative return on assets (ROA) of -47.16%.

However, within the Healthcare sector 569 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2025 from 4062 to 4152.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Oct 31 2024) II. Quarter	(Jul 31 2024) I. Quarter	(Apr 30 2024) IV. Quarter	(Jan 31 2024) III. Quarter	(Oct 31 2023) II. Quarter
Y / Y Total Assets Change	-31.64 %	-26.59 %	-27.96 %	-0.37 %	1.9 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-152	-144	-141	-18	-12
Return On Assets (TTM)	-47.16 %	-40.58 %	-36.85 %	-4.37 %	-2.97 %
CDMO's Total Ranking	# 4152	# 4062	# 4071	# 3618	# 3149
Total Assets (TTM) in million	284	295	296	415	415
Seq. Total Assets Change	-3.89 %	-0.09 %	-28.81 %	0.01 %	3.21 %
Seq. Net Income Change	-	-	-	-	-

CDMO's 5 Years Annual ROA >> Back to CDMO Management Effectiveness >> Compare CDMO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 236
Sector	# 570
Overall	# 4077

Return On Assets Statistics
High	Average	Low
38.8 %	-22.25 %	-79.28 %
(Apr 30 2022)		(Apr 30 2013)

Financial Statements
Avid Bioservices Inc 's Assets	$ 284 million	CDMO's Balance sheet
Avid Bioservices Inc 's Income	$ -17 million	Quarterly CDMO's Income Statement
CDMO's Income by Division		See CDMO's Income by Division

Annual Return On Assets	(Apr 30 2024) FY 2024	(Apr 30 2023) FY 2023	(Apr 30 2022) FY 2022	(Apr 30 2021) FY 2021	(Apr 30 2020) FY 2020
Y / Y Total Assets Change	-27.96 %	4.12 %	58.7 %	182.54 %	12.08 %
Total Assets in million	296	410	394	248	88
Y / Y Net Income Change	-	-99.8 %	1038.71 %	-	-
Net Income in million	-141	0	128	11	-10
Annual Return On Assets	-47.63 %	0.06 %	32.41 %	4.52 %	-11.91 %

CDMO's 5 Years Annual ROA >> Back to CDMO Management Effectiveness >> Compare CDMO ROA to its Competitors

More Return On Assets Ratios
CDMO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CDMO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CDMO's Competitors
Subscribers only: Roa for Avid Bioservices Inc 's Suppliers
Subscribers only: Return On Assets for CDMO's Customers

You may also want to know
CDMO's Roi	CDMO's Inventory Turnover Ratio	CDMO's Growth Rates	CDMO's Dividend Comparisons
	CDMO's Profitability Ratios	CDMO's Asset Turnover Ratio	CDMO's Dividend Growth
CDMO's Roe	CDMO's Valuation Ratios	CDMO's Financial Strength Ratios	CDMO's Dividend Payout Ratio

Companies with similar Return On Assets at Oct 31 2024, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.